Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Prescriptions and children].

E Autret-Leca1, L Bensouda-Grimaldi, C Le Guellec

  • 1Service de Pharmacologie, Centre Régional de Pharmacovigilance et d'Information sur le Médicament, CHRU de Tours, Hôpital Bretonneau, Université François-Rabelais de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 09, France. autret-leca@med.univ-tours.fr

Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|December 14, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The latest updates on the proper use of fluoroquinolones - Actualisation 2025 update by the SPILF and the GPIP.

Infectious diseases now·2025
Same author

The cardiovascular safety of oral alitretinoin: a population-based cohort study involving 19 513 patients exposed to oral alitretinoin.

The British journal of dermatology·2021
Same author

[Contraception: CNGOF Guidelines for Clinical Practice (Short Version)].

Gynecologie, obstetrique, fertilite & senologie·2018
Same author

[The pictogram "Drug and Pregnancy" : Good intentions but difficulties in sight].

Gynecologie, obstetrique, fertilite & senologie·2018
Same author

Psychiatric disorders, acne and systemic retinoids: comparison of risks.

Expert opinion on drug safety·2017
Same author

[Safety profile of etonogestrel contraceptive implant (Nexplanon<sup>®</sup> and Implanon<sup>®</sup>) reported in France].

Journal de gynecologie, obstetrique et biologie de la reproduction·2016
Same journal

Family experiences of paediatric palliative care during hospital-at-home: a systematic review.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
Same journal

Knowledge of maternity caregivers on vaccination BCG recommendations and circuits.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
Same journal

"CRANIOQUALITY study: Quality of life in children with non-syndromic craniosynostosis after surgery".

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
Same journal

Chronological evolution of brain imaging of hemiconvulsion-hemiplegia-epilepsy from 5 cases in Mayotte island.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
Same journal

Point-of-care capillary blood ketone testing to predict the need for intravenous or nasogastric tube rehydration in children with acute gastroenteritis.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
Same journal

Transition practices of patients with inflammatory bowel disease from pediatric to adult healthcare systems. Results from a national survey.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
See all related articles

Pediatric drug evaluation is lacking, leading to off-label prescriptions and increased risks for children. Careful consideration of drug safety and efficacy in pediatric populations is crucial for minimizing adverse events.

Area of Science:

  • Pediatric Pharmacology
  • Drug Safety Evaluation
  • Clinical Pharmacology

Context:

  • Limited drug evaluation in children results in frequent off-label prescriptions.
  • Pharmacokinetic and pharmacodynamic changes during development necessitate specific pediatric drug assessment.
  • Newborns face heightened drug-related risks due to immature metabolism and off-label use.

Purpose:

  • Highlight the critical need for robust drug evaluation in pediatric populations.
  • Address the challenges and risks associated with extrapolating adult drug data to children.
  • Inform healthcare providers about specific pediatric drug considerations and risks.

Summary:

  • Off-label drug use in children is common due to a lack of dedicated evaluations.
  • Physiological immaturity in pediatric patients impacts drug metabolism and response.

Related Experiment Videos

  • Specific adverse effects in children can arise from developmental factors and medication errors.

    • Impact:

    • Emphasizes the importance of adhering to pediatric labeling and considering risks.
    • Advocates for justified off-label prescribing based on potential benefits and risk assessment.
    • Aims to improve medication safety and therapeutic outcomes in pediatric patients.